AbbVie
CompanyUnited StatesFounded 2012
AbbVie develops 57 assets, the furthest approved (ABBV-951). Mostly small molecule and antibody acting on VEGFA, ADRB1 and SNAP25; based in the United States, founded in 2012.
- 57
- Assets
- Furthest stage
- Approved
- 961
- Trials
- 195
- Signals
Pipeline
57Prodrugs supply levodopa and carbidopa, restoring brain dopamine while inhibiting peripheral levodopa breakdown.
Approved, Small molecule, ADRB1, Parkinson's disease (Phase 3)
Enteral suspension of dopamine precursor levodopa and DOPA decarboxylase inhibitor carbidopa.
Approved, Small molecule, advanced Parkinson disease, motor fluctuations
Blocks endothelin A receptor signaling involved in tumor growth and survival.
Approved, Small molecule, EDNRA, IgA nephropathy, primary immunoglobulin a nephropathy
54 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
179 assets, 222 trials
6 assets, 60 trials
1 asset, 36 trials
1 asset, 29 trials
1 asset, 14 trials
1 asset, 8 trials
Chase Pharmaceuticals Corporation
1 asset, 4 trials
1 asset, 2 trials
1 asset, 1 trial
1 asset
1 asset
Allergan Pharmaceuticals International
1 asset
1 asset
8 trials
5 trials
5 trials
3 trials
In the full profile
- Evidence behind the mechanisms11
- Trials1,320
- Deals1
- People1
- Signals20
- Integrity notices1
- Similar companies6
Papers
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Oct 19, 2026
Immune boosting to combat Alzheimer's disease: Position statement
Journal of Alzheimer's disease : JAD, Sep 30, 2026
Cancers, Sep 15, 2026
The journal of prevention of Alzheimer's disease, Jul 10, 2026
Older rat lungs had a more stable support network
bioRxiv (Cold Spring Harbor Laboratory), Jun 22, 2026
Hematological oncology, Mar 18, 2026
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Mar 12, 2026
Aging and cancer, Mar 2, 2026
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks
Nature medicine, Feb 20, 2026
Statistics in medicine, Feb 19, 2026
Comorbidities associated with mild cognitive impairment and Alzheimer's disease in the United States
Journal of Alzheimer's disease : JAD, Jan 27, 2026
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia
Blood, Jan 13, 2026
Plasma biomarkers move at different rates across the Alzheimer's disease continuum
AAIC 2025 abstract, Jan 8, 2026
Short‐interval common game play distinguishes people with and without cognitive impairment
AAIC 2025 abstract, Dec 26, 2025
Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock
AAIC 2025 abstract, Dec 24, 2025
Multiomics Patterns and Alzheimer’s Disease Risk
AAIC 2025 abstract, Dec 23, 2025
Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease
Alzheimer's & dementia : the journal of the Alzheimer's Association, Oct 24, 2025
Nature aging, Aug 6, 2025
Scientific reports, Apr 23, 2025
A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment
Cancer research, Mar 4, 2025